Soligenix, Inc. financial data

Symbol
SNGX on Nasdaq
Industry
Pharmaceutical Preparations
Location
29 Emmons Drive, Suite B 10, Princeton, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Former names
DOR BIOPHARMA INC (to 9/29/2009), ENDOREX CORP (to 10/24/2001), IMMUNOTHERAPEUTICS INC (to 4/30/1996)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 150 % +17.3%
Debt-to-equity 256 % -95.6%
Return On Equity -257 % +93.6%
Return On Assets -72.2 % -6.12%
Operating Margin -1.57K % -50.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.28M shares -76.8%
Common Stock, Shares, Outstanding 1.54M shares -84.3%
Entity Public Float 6.85M USD -73.4%
Common Stock, Value, Issued 1.54K USD -84.3%
Weighted Average Number of Shares Outstanding, Basic 1.26M shares +178%
Weighted Average Number of Shares Outstanding, Diluted 1.26M shares +178%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 495K USD -50.4%
Cost of Revenue 451K USD -33.2%
Research and Development Expense 3.2M USD -45.4%
General and Administrative Expense 4.62M USD -5.56%
Operating Income (Loss) -7.78M USD +25.4%
Nonoperating Income (Expense) 130K USD +447%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.65M USD +29.7%
Income Tax Expense (Benefit) -1.16M USD
Net Income (Loss) Attributable to Parent -7.04M USD +27.6%
Earnings Per Share, Basic 1.64 USD/shares +63.2%
Earnings Per Share, Diluted 1.64 USD/shares +63.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.9M USD -25.1%
Assets, Current 9.66M USD -28.3%
Property, Plant and Equipment, Net 8.75K USD -42.1%
Operating Lease, Right-of-Use Asset 171K USD -40.4%
Other Assets, Noncurrent 3.88K USD -80%
Assets 9.87M USD -28.7%
Accounts Payable, Current 1.7M USD -31.3%
Employee-related Liabilities, Current 80.2K USD +8.64%
Accrued Liabilities, Current 1.7M USD -27.5%
Contract with Customer, Liability, Current 100K USD
Liabilities, Current 6.35M USD +10.4%
Contract with Customer, Liability, Noncurrent 100K USD
Operating Lease, Liability, Noncurrent 45.7K USD -73.8%
Liabilities 6.4M USD -20.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 27.6K USD +355%
Retained Earnings (Accumulated Deficit) -229M USD -3.17%
Stockholders' Equity Attributable to Parent 3.46M USD -40.3%
Liabilities and Equity 9.87M USD -28.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.34M USD +38%
Net Cash Provided by (Used in) Financing Activities -8.99K USD +99%
Net Cash Provided by (Used in) Investing Activities -9.82K USD
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 1.54M shares -84.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.35M USD +56.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.41M USD -28.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 64K USD -70%
Deferred Tax Assets, Valuation Allowance 40.4M USD +1.24%
Cash and Cash Equivalents, Period Increase (Decrease) 3.17M USD
Deferred Tax Assets, Gross 40.5M USD +1.16%
Operating Lease, Liability 368K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.02M USD +27.8%
Lessee, Operating Lease, Liability, to be Paid 234K USD -39.6%
Operating Lease, Liability, Current 129K USD +11.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 116K USD -15.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 137K USD +2.32%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19.5K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 116K USD
Deferred Tax Assets, Operating Loss Carryforwards 27.5M USD +0.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 350K shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 26.3K USD -15.1%
Additional Paid in Capital 233M USD +2.06%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 33.5K USD -37.5%
Deferred Tax Assets, Net of Valuation Allowance 65K USD -32.3%